Destiny Pharma welcomes new CEO

Destiny Pharma, a clinical stage biotech company focused on the development of new anti-microbial drugs, has appointed Neil Clark as Chief Executive Officer (CEO) and member of the Board of Directors, effective immediately.

Destiny’s scientific founder and previous CEO, Dr Bill Love, has been appointed to Chief Scientific Officer (CSO), the company said in its press release.

Sir Nigel Rudd, Non-Executive Chairman of Destiny Pharma, commented:

“Destiny has made significant progress in the last two years, concluding in 2016 with very encouraging results from a National Institute of Health-sponsored proof-of-concept clinical study with XF-73, the lead drug from our XF drug platform. As we move forward, Neil’s extensive leadership experience in clinical stage biopharmaceutical companies will be invaluable as Destiny starts planning its first Phase IIb clinical trial. In this trial, the Company will be investigating XF-73 as a potential first-in-class drug for the prevention of post-surgical infections from all strains of Staphylococcus aureus, which we believe is a blockbuster opportunity.”

“Bill Love, the founder of the Company, will continue his scientific leadership of Destiny in the newly created role of Chief Scientific Officer. As a recognised thought leader in combating the global issue of anti-microbial resistance, he will continue to focus on developing the XF platform and earlier stage projects, as the Company seeks to expand and further strengthen its already robust intellectual property position.”